GE Healthcare has paid $30 million to settle allegations that one of its subsidiaries violated the False Claims Act by providing misleading information to Medicare that resulted in overpayments, according to a news release from the Department of Justice.
Amersham Health, which GE acquired in 2004, allegedly provided false information for a drug called Myoview, which is used in certain cardiac diagnostic imaging procedures. The drug is distributed in multi-dose vials of powder, and the government claims Amersham incorrectly stated the number of doses available from those vials. Medicare subsequently paid for allegedly inflated rates, according to the release.
The suit was filed by whistleblower James Wagel, who will receive $5.1 million from the government's recovery.
KV Pharmaceutical to Pay $17M to Resolve False Claim Charges
GlaxoSmithKline Settles Case Over Drug Pricing, Marketing With $3B
Amersham Health, which GE acquired in 2004, allegedly provided false information for a drug called Myoview, which is used in certain cardiac diagnostic imaging procedures. The drug is distributed in multi-dose vials of powder, and the government claims Amersham incorrectly stated the number of doses available from those vials. Medicare subsequently paid for allegedly inflated rates, according to the release.
The suit was filed by whistleblower James Wagel, who will receive $5.1 million from the government's recovery.
Related Articles on Pharmaceutical Fraud:
Merck Agrees to Pay $24M to Massachusetts' Medicaid ProgramKV Pharmaceutical to Pay $17M to Resolve False Claim Charges
GlaxoSmithKline Settles Case Over Drug Pricing, Marketing With $3B